Paige has announced a partnership with Sonora Quest Laboratories for implementing a completely digital pathology workflow at the latter’s laboratories in Arizona, US.
This digital transformation project aims to improve current diagnostic workflows and expedite precision diagnostics for patients across the region.
Under the collaboration deal, Paige will be responsible for providing the complete suite of its artificial intelligence (AI)-powered digital pathology solutions, including Paige Breast, FullFocus viewer and Paige Prostate Detect, to Sonora Quest.
The Paige Breast Suite consists of Paige Breast and Paige Breast Lymph Node. Its suite of AI applications are designed to support pathologists evaluate breast cancer.
They also identify cancer in breast biopsies and metastases in breast lymph nodes.
Paige Prostate Detect is claimed to be the first AI-based pathology product to obtain de novo marketing authorisation from the US Food and Drug Administration (FDA).
This allows it to be used as an in vitro diagnostic (IVD) through the company’s FullFocus digital pathology viewer.
Paige CEO Andy Moye said: “The implementation of Paige products at Sonora Quest further validates our ability to scale and deploy our technology to meet the demands of a high-volume commercial laboratory.
“AI software, like Paige Prostate Detect, can serve as a built-in second opinion to promote diagnostic confidence and help reduce diagnostic errors. We believe that our integrated solution can ultimately streamline and improve patient care.”
The company stated that Sonora Quest aims to use AI, cloud-based platforms to improve patient care and experiences, expedite precision diagnosis to enhance diagnostic and health outcomes, and reduce care costs.
Sonora Quest will be able to share the data regarding cases with clinicians through virtualisation.
This will improve access to specialists, reduce the interpretation errors rate and optimise workloads.
In March, Paige introduced Paige Breast Lymph Node, an AI medical device software to identify breast cancer metastases in lymph nodes.